How Does a Nebulizer Work? Jet, Ultrasonic, and Vibrating Mesh Explained — Biomedical Engineering Guide

A nebulizer is a device that converts a liquid drug solution into a fine aerosol mist that a patient inhales directly into the lungs, bypassing the coordination problems of a handheld inhaler. There are three working technologies, and they are not interchangeable: a jet nebulizer uses compressed air blown through a narrow nozzle to shear the liquid into droplets (a classic Venturi/Bernoulli effect); an ultrasonic nebulizer uses a piezoelectric crystal vibrating at 1.2–2.4 MHz beneath the liquid reservoir to shake droplets off the surface; and a vibrating-mesh nebulizer forces liquid through thousands of laser-drilled, micron-sized holes in a mesh or aperture plate that is itself vibrated at ultrasonic frequency. Mesh devices are now the fastest, most efficient, and most portable of the three — one head-to-head mouse study found a vibrating-mesh device delivered 141.7% as much drug to the lung as a comparable jet nebulizer, despite the jet nebulizer producing nominally smaller droplets.

Everything below unpacks that definition layer by layer — starting from why aerosol delivery exists at all, through to how each type is built, operated, tested, maintained, and where the field is heading next.

---

A practical, numbers-first guide for biomedical engineers — physics, device architecture, procedure, QA/testing, safety, and where the technology is heading, built on verified 2019–2026 literature.

1. Why aerosol drug delivery needs a dedicated device

Inhaled therapy puts drug directly where it needs to act — the airway smooth muscle and mucosa — at a fraction of the oral or IV dose, cutting systemic side effects. But turning a liquid drug into particles small enough to reach the lower airway (roughly 1–5 µm) without a patient’s active breath-hold or perfect inhaler technique is a nontrivial fluid-mechanics problem. Metered-dose inhalers and dry-powder inhalers solve it with propellant or the patient’s own inspiratory effort, but both require hand-breath coordination that many patients cannot manage — young children, the elderly, anyone with impaired dexterity or cognition, or a patient too breathless to generate a strong inspiratory flow. A nebulizer solves this by generating a continuous aerosol cloud the patient simply breathes normally through a mouthpiece or mask, over several minutes, no coordination required. Surveyed pulmonologists rank persistent symptoms despite handheld-inhaler use (average importance rating 4.56/5.0) and patient dexterity/hand-mouth coordination problems (4.46/5.0) as the top two reasons they switch a patient to nebulized therapy.²

2. Working principle: three physically different ways to make an aerosol

All three nebulizer types are trying to hit the same target — a Mass Median Aerodynamic Diameter (MMAD), the particle size at which half the aerosol’s mass is carried by particles larger than that diameter and half by particles smaller, ideally in the 1.5–5.8 µm range for lower-airway deposition³ — but they get there by different physics:

• Jet (pneumatic) nebulizer. A compressor or wall gas supply drives compressed air at high velocity through a narrow Venturi nozzle positioned just above the liquid reservoir. The pressure drop across the nozzle draws liquid up a feed tube (the Bernoulli effect) and shears it into a polydisperse spray as it meets the air jet. A baffle immediately downstream recaptures the larger droplets, which fall back into the reservoir for re-nebulization, while only the fine fraction escapes to the patient. Because the baffle recirculates most of the liquid many times before it is small enough to escape, jet nebulizers have the highest residual (wasted) drug volume of the three designs — 27–34.6% of the charged dose in one comparative study.¹
• Ultrasonic nebulizer. A piezoelectric crystal beneath the liquid reservoir vibrates at 1.2–2.4 MHz; the resulting capillary waves at the liquid surface break it into a polydisperse aerosol with no compressor and no baffle recirculation loop.⁴ Ultrasonic devices are largely absent from the current hospital/home comparison literature because the high-frequency vibration transmits heat into the drug reservoir and can denature protein-based and suspension formulations (e.g., budesonide suspension, dornase alfa) — a real constraint on which drugs a given nebulizer type can deliver.
• Vibrating-mesh nebulizer. A mesh or aperture plate perforated with hundreds of laser-drilled holes (typically a few microns in diameter) is vibrated at ultrasonic frequency, either by a piezoelectric ring bonded directly to the mesh (active/vibrating mesh) or by a separate ultrasonic horn driving a static mesh from behind (static mesh). Liquid is drawn through the holes and ejected as a fine, low-velocity aerosol with almost no residual volume (<1% in the same comparative study) because there is no baffle recirculating unused drug back into the reservoir.¹

Parameter (salbutamol, comparative study)	Jet — PARI BOY SX, red nozzle	Jet — PARI BOY SX, blue nozzle	Static mesh — Omron NE-U22	Vibrating mesh — KTMED NE-SM1
MMAD	3.4 µm	4.54 µm	6.83 µm	5.34 µm
Output rate	0.153 mL/min	0.184 mL/min	0.288 mL/min	0.239 mL/min
Residual volume	27%	34.6%	<1%	<1%
Relative lung+serum delivery vs. PARI BOY SX (red)	100% (reference)	—	39.9%	141.7%

Source: Chang KH et al., mouse ELISA delivery-efficiency study.¹ Note the counterintuitive result: the jet nebulizer produced the smallest nominal particles but delivered the least drug, because output rate and residual volume — not particle size alone — dominate total delivered dose.

3. Device architecture and components

Regardless of type, a nebulizer system has the same functional blocks:

1. Medication reservoir/cup — typically 4–6 mL fill capacity, sized so a standard unit dose (e.g., 2.5 mg salbutamol in 2.5–3 mL saline) nebulizes in a clinically practical time.
2. Aerosol-generating element — the jet/Venturi nozzle, the ultrasonic piezoelectric crystal, or the vibrating mesh/aperture plate, per the mechanism above.
3. Baffle system (jet designs only) — recaptures oversized droplets for recirculation back into the reservoir, setting the fine-particle fraction that escapes.
4. Drive source — a piston or diaphragm air compressor (jet), a piezoelectric driver circuit (ultrasonic and mesh), or battery-powered electronics for portable mesh units.
5. Patient interface — mouthpiece, or a face mask (pediatric/elderly), connected via corrugated tubing or directly molded into a handheld unit.
6. Control electronics (modern units) — on/off, and on higher-end devices, breath-actuated or breath-enhanced valves that reduce aerosol loss to the room during exhalation.

4. Regulatory classification

Nebulizers don’t carry a clinical procedure code the way an implant does — instead they carry a device-class designation under the applicable medical-device framework:

• United States — 21 CFR § 868.5640, “Medicinal nonventilatory nebulizer (atomizer),” defined as “a device that is intended to spray liquid medication in aerosol form into the air that a patient will breathe.” It is a Class I device (general controls); FDA nonetheless treats nebulizers and metered-dose inhalers as prescription devices, and manufacturers must hold a cleared 510(k) premarket notification before marketing.⁵
• International standard — ISO 27427:2023 (“Anaesthetic and respiratory equipment — Nebulizing systems and components”), 4th edition, published 2023-07, specifies safety and performance testing for general-purpose nebulizing systems operating in continuous or breath-actuated mode, and standardizes performance verification using a 1% w/v salbutamol test formulation with cascade-impactor MMAD measurement.⁶ It superseded the earlier EN 13544-1 in the EU framework.
• A 2012 comparative analysis of the ISO 20072 (general oral-inhaled-product) and ISO 27427 (nebulizer-specific) standards noted that ISO 27427’s more prescriptive, device-level performance-verification approach — testing the finished system with a single reference drug formulation — is fundamentally different in philosophy from ISO 20072’s risk-assessment-driven Device Functionality Profile approach used for inhalers.⁷

5. Step-by-step operating procedure (jet nebulizer, most common home/clinical setup)

1. Wash hands; assemble the nebulizer cup, mouthpiece/mask, and tubing per the manufacturer’s diagram.
2. Measure the prescribed drug dose (or use a pre-filled unit-dose vial) into the medication cup; add diluent (usually 0.9% saline) only if the drug vial is not already pre-mixed to the correct volume.
3. Connect the cup to the compressor via tubing; connect the mouthpiece or mask to the cup.
4. Have the patient sit upright; switch on the compressor and confirm a visible mist is generated.
5. Instruct the patient to breathe normally through the mouth via the mouthpiece (a mask is used only if mouthpiece use is not possible, since mask use deposits more aerosol on the face/eyes and less in the lung).
6. Continue until the mist visibly thins and sputtering begins (typically 5–15 minutes depending on device output rate and fill volume) — sputtering signals the reservoir is running dry and continuing wastes drug on evaporating residual liquid.
7. Switch off, disconnect, and rinse/air-dry the cup and mouthpiece per the manufacturer’s reprocessing instructions; replace disposable components on the schedule the manufacturer specifies.

6. Materials and power source

• Reservoir and mouthpiece — medical-grade polypropylene or polycarbonate, chosen for chemical compatibility with common nebulized drugs (bronchodilators, corticosteroid suspensions, antibiotics, hypertonic saline, mucolytics) and for autoclave or disinfectant tolerance where the device is reused across patients.
• Mesh/aperture plate (mesh nebulizers) — a thin metal (commonly nickel or stainless-steel) plate laser- or electroform-drilled with hundreds of micron-scale apertures; the aperture geometry, not just count, sets the resulting MMAD.
• Power — jet nebulizers run from an AC-powered piston/diaphragm compressor (bench-top home units) or hospital medical-gas outlets; portable mesh nebulizers run from rechargeable lithium-ion batteries or disposable AA/AAA cells, which is what makes handheld mesh devices practical for ambulatory and pediatric use.

7. QA and testing: what “working correctly” means numerically

• Particle-size distribution / MMAD — verified with a cascade impactor or laser-diffraction system against the ISO 27427 reference salbutamol formulation; acceptance is a defined MMAD range and geometric standard deviation, not a single pass/fail droplet count.⁶
• Output rate (mL/min) and residual volume (% of charge remaining unable to be nebulized) — both measured gravimetrically before and after a timed run; a higher output rate at a clinically relevant MMAD, with lower residual volume, is what actually drives delivered dose, as the jet-vs-mesh comparison above demonstrates.¹
• Fine-particle fraction — the proportion of the aerosol mass below ~5 µm, the fraction actually capable of lower-airway deposition; reported alongside MMAD because two devices with the same MMAD can still differ in how tightly the distribution is centered on the respirable range.
• Follow-up in clinical use — repeat spirometry (FEV1/FVC) or peak-flow trend after a nebulized bronchodilator course is the practical bedside correlate of delivered dose; a nebulizer that meets bench MMAD/output specs but shows no measurable bronchodilator response in a patient warrants a device check (mesh clogging, battery degradation, compressor pressure drop) before assuming drug failure.

8. Complications, safety, and failure modes

• Under-dosing from device choice mismatch — as the comparative data above shows, a jet nebulizer’s high residual volume and lower output rate can deliver well under half the drug a mesh device delivers from the identical nominal dose; a device switch without a dose review is a real clinical risk.¹
• Drug degradation in ultrasonic units — piezoelectric heating of the reservoir can denature suspension or protein-based formulations, which is why ultrasonic nebulizers are not first-line for budesonide suspension or biologic/protein drugs.
• Cross-contamination and infection risk — inadequately cleaned/dried nebulizer cups are a recognized reservoir for bacterial growth (notably Pseudomonas and other gram-negatives) between uses, especially in cystic fibrosis and bronchiectasis patients who nebulize multiple times daily; manufacturer-specified rinse/air-dry (and periodic disinfection) protocols exist specifically to control this.
• Mesh clogging or aperture wear — mesh nebulizers are sensitive to drug crystallization or particulate residue blocking apertures, which drops output rate and shifts MMAD upward (fewer, larger droplets escaping); this is the dominant mesh-specific failure mode requiring cup replacement per the manufacturer’s duty-cycle schedule rather than indefinite reuse.
• Compressor mechanical wear (jet units) — diaphragm/piston wear reduces driving pressure over the compressor’s service life, lowering output rate below the original 510(k)-cleared performance even though the unit still “runs.”

9. Maintenance and troubleshooting

Symptom	Likely cause	Action
Little or no visible mist	Compressor pressure too low / battery low (mesh) / tubing kinked or disconnected	Check tubing connections and battery charge; if compressor pressure is below spec, service or replace
Mist output much weaker than when new	Mesh aperture clogging, or compressor diaphragm wear	Clean mesh per manufacturer protocol (do not scrub/pierce apertures) or replace mesh cup; service compressor if jet type
Treatment time much longer than expected	Reduced output rate as above, or reservoir overfilled beyond rated capacity	Verify fill volume against label; address underlying output issue
Sputtering starts very early	Underfilled reservoir	Recheck dose-mixing instructions
Patient reports no symptomatic benefit despite normal-looking mist	MMAD drifted out of respirable range (aperture wear/clogging), or interface (mask vs. mouthpiece) mismatch	Bench-check output/MMAD if available; switch to mouthpiece if mask was in use and patient can cooperate
Visible residue/discoloration in cup	Inadequate rinse/dry between uses, drug crystallization	Follow manufacturer cleaning/disinfection schedule; replace cup on the specified interval

10. Manufacturer landscape

Manufacturer	Representative product(s)	Technology	Notes
PARI	BOY SX, eFlow, eRapid	Jet (BOY SX); vibrating mesh (eFlow/eRapid)	BOY SX is a widely used comparative-study reference jet device; eFlow-family mesh systems are used in CF and other chronic-therapy programs
Omron Healthcare	NE-U22, CompAir NE-C801/series	Static mesh (NE-U22); jet (CompAir line)	NE-U22 static-mesh performance is a common benchmark in delivery-efficiency literature1
Aerogen	Aeroneb Solo, Aeroneb Pro	Vibrating (active) mesh	Closed-circuit design for use in-line with mechanical ventilator circuits; documented flow rates of roughly 0.23–0.31 mL/min in bench testing of common critical-care drug formulations8
Drive DeVilbiss Healthcare	Traveler, Pulmo-Aide compressor lines	Jet	Long-standing home-care compressor/jet nebulizer manufacturer
Philips Respironics	SideStream and related jet lines	Jet	Established hospital/home jet-nebulizer supplier

11. Choosing between jet, ultrasonic, and vibrating mesh

Factor	Jet	Ultrasonic	Vibrating mesh
Portability	Low (needs compressor, AC power)	Low–moderate	High (battery-powered handheld units exist)
Treatment time (typical 2–3 mL dose)	Longest	Moderate	Shortest
Residual (wasted) drug volume	Highest (27–35%)	Moderate	Lowest (<1%)
Suitable for suspensions/protein drugs	Yes	Often no (heating denatures formulation)	Yes
Typical cost	Lowest	Moderate	Highest
Best fit	Cost-sensitive home use, drugs incompatible with mesh	Niche/legacy use	Portable, ventilator-circuit, and dose-sensitive (CF, biologics) therapy

12. Future directions

Vibrating-mesh technology is displacing both jet and ultrasonic designs across new product launches because of its combination of low residual volume, portability, and formulation compatibility — the delivery-efficiency gap documented above is a major driver. In parallel, the inhaled-biologics pipeline (monoclonal antibodies, nucleic-acid therapeutics, and other large-molecule candidates for respiratory, infectious, and pulmonary-fibrosis indications) is expanding, which will keep pushing nebulizer design toward gentler, non-thermal aerosolization — exactly the profile mesh technology already offers over ultrasonic units.⁹ Breath-actuated and closed-circuit ventilator-integrated mesh designs (as used in critical care) are also extending nebulizer use into settings that previously relied on less efficient in-line jet adaptors.

Conclusion

A nebulizer’s clinical performance is set by which of three physically distinct aerosol-generation mechanisms it uses — jet, ultrasonic, or vibrating mesh — and the numbers matter more than the marketing: a device with smaller nominal droplets is not automatically the better drug-delivery system once output rate and residual volume are accounted for. Vibrating-mesh nebulizers now lead on efficiency and portability for most indications, jet nebulizers remain the low-cost, formulation-flexible workhorse, and ultrasonic units occupy a shrinking niche limited by their unsuitability for suspension and biologic drugs.

FAQ

Is a jet nebulizer “worse” than a mesh nebulizer? Not universally — it delivers less of the nominal dose per the comparative data above, but it remains compatible with drug formulations (some suspensions) that can clog or be degraded by mesh/ultrasonic designs, and it is lower cost.

Why does mist output slow down near the end of a treatment? The reservoir is running low and the remaining film of liquid is too thin to nebulize efficiently — this “sputtering” is a normal end-of-dose signal, not a malfunction, provided it happens near the expected treatment duration.

Can any nebulizer be used with any drug? No — always follow the drug label and device manufacturer’s compatibility guidance; heating (ultrasonic) or shear forces (jet) can degrade some suspensions and biologics, which is one reason mesh nebulizers dominate CF and biologic-drug delivery.

Do nebulizers need prescriptions? In the US, FDA treats all nebulizers as prescription devices even though the base device class (21 CFR 868.5640) is Class I.⁵

References